Clinical Trial

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Name: Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT06581640)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the safety and tolerability of chimeric antigen receptor gene-modified T cells targeting BCMA for the treatment of relapsed/refractory multiple myeloma

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-08-30.

Trial Details

NCT Number	NCT06581640
Lead Sponsor	The First Affiliated Hospital of Xiamen University
Conditions	Multiple Myeloma, Relapsed/Refractory
Enrollment	5 participants
Start Date	2024-09-24
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-09-25